Amyloid-beta (Aβ) is thought to play a central role in synaptic dysfunction (e.g. neurotransmitter release) and synapse loss. Glutamatergic dysfunction is involved in the pathology of Alzheimer's disease (AD) and perhaps plays a central role in age-related cognitive impairment. Yet, it is largely unknown whether Aβ accumulates in excitatory boutons. To assess the possibility that glutamatergic terminals are lost in AD patients, control and AD synaptosomes were immunolabeled for the most abundant vesicular glutamate transporters (VGluT1 and VGluT2) and quantified by flow cytometry and immunoblot methods. In post-mortem parietal cortex from aged control subjects, glutamatergic boutons are fairly abundant as approximately 40% were immunoreactive for VGluT1 (37%) and VGluT2 (39%). However, the levels of these specific markers of glutamatergic synapses were not significantly different among control and AD cases. To test the hypothesis that Aβ is associated with excitatory terminals, AD synaptosomes were double-labeled for Aβ and for VGluT1 and VGluT2, and analyzed by flow cytometry and confocal microscopy. Our study demonstrated that Aβ immunoreactivity (IR) was present in glutamatergic terminals of AD patients. Quantification of Aβ and VGluT1 in a large population of glutamatergic nerve terminals was performed by flow cytometry, showing that 42% of VGluT1 synaptosomes were immunoreactive for Aβ compared to 9% of VGluT1 synaptosomes lacking Aβ-IR. Percentage of VGluT2 synaptosomes immunoreactive for Aβ (21%) was significantly higher than VGluT2 synaptosomes lacking Aβ-IR (9%). Moreover, Aβ preferentially affects VGluT1 (42% positive) compared to VGluT2 terminals (21%). These data represent the first evidence of high levels of Aβ in excitatory boutons in AD cortex and support the hypothesis that Aβ may play a role in modulating glutamate transmission in AD terminals.
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Introduction
Alzheimer's disease (AD) is the most common form of dementia, affecting N 5 million Americans (Hebert et al., 2003) . Abnormal amyloid-beta (Aβ) metabolism, tau hyperphosphorylation and synapse loss are characteristic features of AD. Although the molecular triggers of AD are unknown, extensive studies indicate that Aβ plays a principal role in AD pathogenesis (Kuo et al., 1996; McLean et al., 1999; Naslund et al., 2000) .
Presynaptic buildup of soluble Aβ is suggested as a proximal cause of synapse dysfunction in AD (Fein et al., 2008; Shankar et al., 2007; Shankar et al., 2008) . Natural human Aβ dimers are able to (i) mediate loss of dendritic spines and excitatory synapses; (ii) inhibit long-term potentiation (LTP) and facilitate long-term depression (LTD) in normal rodent hippocampus, and (iii) impede learned behavior in normal rats (Shankar et al., 2007; Shankar et al., 2008) . The degree of clinical impairment strongly correlates to the decrease of electrophysiologically active synapses especially glutamatergic pyramidal synapses (Shankar et al., 2007; Shankar et al., 2008; Terry et al., 1991) . Nonetheless, a direct link between Neurobiology of Disease 45 (2012) [381] [382] [383] [384] [385] [386] [387] 
